ArticleInternational journal of clinical and experimental pathology2014
Undifferentiated embryonal sarcoma of liver: a multi-institutional experience with 9 cases.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Undifferentiated embryonal sarcoma of the liver in an 11-year-old boy: a case report and clinical insights.Frontiers in surgery · 2026Article
- Case Report: Adult UESL mimicking a simple hepatic cyst and initially misdiagnosed as a benign lesion.Frontiers in oncology · 2025Article
- Case Report: Undifferentiated embryonic sarcoma of an adult liver.Frontiers in oncology · 2025Article
- Review
- Undifferentiated Embryonal Sarcoma of the Liver in Children Versus Adults: A National Cancer Database Analysis.Cancers · 2021Article
- Diagnosis and Treatment of an Undifferentiated Embryonal Sarcoma of the Liver in a 37-Week Pregnant Woman: A Case Report.International journal of women's health · 2021Article
- Undifferentiated embryonal sarcoma of the liver in adults: Retrospective analysis of a case series and systematic review.Oncology letters · 2020Article
- Hanging Undifferentiated Embryonal Sarcoma of the Liver in Adult: an Unusual Presentation of an Aggressive Tumor.Journal of gastrointestinal cancer · 2019Article
- Pulmonary Metastases from an Undifferentiated Embryonal Sarcoma of the Liver: A Case Report and Review.Case reports in oncological medicine · 2018Article
- Unexpected Liver Embryonal Sarcoma in the Adult: Diagnosis and Treatment.Case reports in surgery · 2018Article
- Characteristics and outcomes in children with undifferentiated embryonal sarcoma of the liver: A report from the National Cancer Database.Pediatric blood & cancer · 2017Article
- A single-center experience with undifferentiated embryonal sarcoma of the liver.Pediatric blood & cancer · 2016Article
- Undifferentiated embryonal sarcoma of the liver in a young female: treatment with portal vein embolization and liver trisectonectomy.Korean journal of hepato-biliary-pancreatic surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To summarize the clinicopathological features, therapeutic regimens and outcomes for the patients with undifferentiated embryonal sarcoma of the liver (UESL), 9 cases of UESL were retrospectively reviewed. Complete clinical history, lab studies, imaging examinations and pathological findings were collected for analysis. Overall survival and progression free survival were assessed by Kaplan-Meier Survival Analysis. The patients were 6 to 37 years old, and included 6 males and 3 females. The tumor size ranged from 5 to 26 cm. Pathologically, the tumors consisted of proliferations of medium sized spindle, oval or stellate shaped pleomorphic cells loosely or compactly arranged in an edematous or myxoid matrix, with scattered bizarre multinucleated giant cells. All of the 9 cases were treated with radical resections, 6 of 9 cases received chemothrepy for postoperative treatment. All follow-up data were available, 4 of 9 cases had recurrence, and 2 patients were died. Time to recurrence in these cases was 19, 4, 29, 14 months. The mean overall survival (OS) was 58.25 ± 9.1 months and the mean progression-free survival (PFS) was 39.55 ± 11.6 months. UESL is a potential treatable malignance when treated with combined multiagent chemotherapy after resection.
Indexed as
Identifiers
25674229PMC4313983W2400667023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.